MetaCap

Femasys (FEMY) vs Fractyl Health (GUTS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Femasys (FEMY) has outperformed Fractyl Health (GUTS) over the past year, losing 93.3% versus a loss of 95.1%. Fractyl Health is the larger company by market cap ($10.9 million vs $10.7 million), about 1.0 times the size, while Femasys is growing revenue faster (+40.8% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FEMY-93.26%GUTS-95.12%
+78%-13%-103%
Nov 21, 20251 yearNov 20, 2026
FEMY-92.05%GUTS-99.47%
+175%+31%-113%
Jan 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FEMY versus GUTS key metrics
MetricFEMYGUTS
Share price$1.24$0.82
Market cap$10.73M$10.88M
1-day change0.00%-14.16%
YTD return-89.24%-96.89%
1-year return-93.26%-95.12%
5-year return-98.63%—
EPS (TTM)$-1.79$-3.14
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.29M$0
Revenue growth (YoY)+40.77%-100.00%
Net income (latest FY)$-18.63M$-140.95M
Gross margin61.96%—
Operating margin-766.95%—
Net margin-812.27%—
52-week high$20.80$29.34
52-week low$1.07$0.784
Distance from 52-week high-94.04%-97.21%
Analyst consensusnonestrong_buy
Avg. price target upside+1055.65%+7265.85%
Average volume110.75K504.39K
Shares outstanding8.66M13.26M
Employees51100
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Femasys grew revenue faster in its latest fiscal year (+40.77% vs -100.00%).

About Femasys

FEMY stock →

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.

Health Care · Medical/Dental Instruments · 51 employees

About Fractyl Health

GUTS stock →

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

Health Care · Medical/Dental Instruments · 100 employees

FEMY vs GUTS FAQ

Which is bigger, Femasys or Fractyl Health?

Fractyl Health (GUTS) is larger, with a market capitalization of $10.88M compared with $10.73M for Femasys (FEMY).

Which stock has performed better over the past year, FEMY or GUTS?

FEMY returned -93.26% over the past 12 months, compared with -95.12% for GUTS (price return, excluding dividends). Past performance does not predict future results.

Are Femasys and Fractyl Health in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons